{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 28,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a side-by-side comparison layout to delineate two distinct clinical trial phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/19",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.43,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "list",
      "text": "Objective: Early POC data + dose range estimation for phase 2. Key Assessments: EEG-based maintenance of wakefulness test, Drug exposure (PK), Safety and tolerability. Study initiation H1 2023; Preliminary data year-end.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "050a8332-3036-4012-8453-a7e77a0101cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.43,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "Objective: Measure and model pharmacokinetics (PK)/ pharmacodynamics (PD) and evaluate safety and tolerability of single and multiple ascending doses. Key Assessments: Drug exposure (PK), Evaluate safety and tolerability. Exploratory assessment: qEEG trends.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9a9d722-2344-4e96-8a30-93651bf01ab7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Phase 1b Proof-of-Concept (POC) Study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "023fead2-47d9-4d72-b203-6f8c5ae69ca1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Phase 1 First-in-Human (FIH) Studies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5bb85f4-c05d-415c-bb87-785279159f7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "EEG: electroencephalogram; qEEG: quantitative electroencephalogram",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52fb0c2d-d2c3-48a9-b168-3f96c433f8fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 2680 Clinical Development Plan Targeting Clinical Proof-of-Concept Data by Year-End 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b28a010d-eeb8-430a-be6d-d80e5822e423",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 13,
      "beatId": "455311ba-8ac4-47bd-a45a-0bcdde58b22a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck outlines clear priorities and a roadmap for growth.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 13,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "720f4a4f-461e-4591-8c2c-8988df913da8",
      "evidence": "The deck presents the clinical development plan and timeline.",
      "position": 1,
      "objective": "Why is now the right time to advance the orexin 2 receptor agonist?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}